6:27 AM ET
8-K
Clinical Trial Data
Rezolute Clinical Trial Data
Rezolute announced positive preliminary results from its Phase 3 upLIFT study of ersodetug in patients with tumor hyperinsulinism. The study met its primary efficacy endpoint with 13 of 16 participants achieving at least a 50% reduction in glucose infusion rate, including 12 who completely discontinued IV glucose. The company expects to report full topline results in mid-December 2026 and engage with the FDA in Q1 2027.
- Term
- 8 weeks